Related Experiment Video
Updated: Jul 17, 2026

Bioluminescence Imaging to Detect Late Stage Infection of African Trypanosomiasis
Published on: May 18, 2016
Availability and affordability of treatment for Human African Trypanosomiasis
M G Etchegorry1, J P Helenport, B Pecoul
1Médecins Sans Frontières, 8 Rue Saint Sabin, Paris.
Abstract:
Human African Trypanosomiasis (HAT) is a re-emerging disease whose usual treatments are becoming less efficient because of the increasing parasite resistance. Availability of HAT drugs is poor and their production in danger because of technical, ecological and economic constraints. In view of this dramatic situation, a network involving experts from NGOs, WHO and pharmaceutical producers was commissioned with updating estimates of need for each HAT drug for the coming years; negotiations with potential producers of new drugs such as eflornithine; securing sustainable manufacturing of existing drugs; clinical research into new combinations of these drugs for first and second-line treatments; centralizing drug purchases and their distribution through a unique non-profit entity; and addressing regulatory and legal issues concerning new drugs.
Related Concept Videos
Malaria
Toxoplasmosis
American Trypanosomiasis
Trichomoniasis
Anthelminthic Agents
Antiprotozoal Agents

